the acorda therapeutics ( acorda ) launch has been a gradual than expected. however, multiple inputs continue to support our conviction that a substantial product and indeed a standard of care in the treatment of OFF periods in Parkinson's. these inputs include our own formal market research and independent market research. we will discuss key events in the second quarter and we will discuss key issues and insights. we also implemented a corporate restructuring to extend the time that we will need to establish a strong trajectory for the ibrja launch as well as to provide flexibility for us to address the company's convertible note that's due in the 2021.